The Lancet. Haematology
Overview
The Lancet. Haematology is a prestigious medical journal that focuses on the latest advancements in the field of haematology. It publishes high-quality research articles, reviews, and commentaries, providing valuable insights into the diagnosis, treatment, and management of blood disorders. With its rigorous peer-review process and global reach, this journal serves as a vital resource for haematologists, researchers, and healthcare professionals seeking to stay updated with cutting-edge developments in haematology.
Details
Details
Abbr.
Lancet Haematol
Start
2014
End
Continuing
Frequency
Monthly, 2015-
e-ISSN
2352-3026
Country
United Kingdom
Language
English
Specialties
Oncology
Hematology
Hematology
Metrics
Metrics
h-index / Ranks: 3490
93
SJR / Ranks: 380
3923
CiteScore / Ranks: 197
25.50
JIF / Ranks: 115
24.7
Recent Articles
1.
2.
Abboud M, Cancado R, De Montalembert M, Smith W, Rimawi H, Voskaridou E, et al.
Lancet Haematol
. 2025 Mar;
PMID: 40088922
Background: Crizanlizumab has previously shown efficacy as a potent disease-modifying therapy for alleviating vaso-occlusive crisis in sickle cell disease. The SUSTAIN study showed a reduction of vaso-occlusive crises in patients...
3.
4.
Malpica L, Idrobo H, Pavlovsky A, Miranda E, Castro D, Beltran B, et al.
Lancet Haematol
. 2025 Mar;
PMID: 40056928
Background: Peripheral T-cell lymphomas represent a rare and heterogeneous group of mature T-cell neoplasms characterised by aggressive behavior. Previous studies evaluating peripheral T-cell lymphoma epidemiology across Latin America have been...
5.
Tecayehuatl-Negrete L, Peralta-Amaro A, Romero-Cuevas K, Zuniga-Espinosa J, de Leon R
Lancet Haematol
. 2025 Mar;
12(3):e230.
PMID: 40044258
No abstract available.
6.
Chin-Yee B, Laplane L, Sujobert P
Lancet Haematol
. 2025 Mar;
12(3):e224-e229.
PMID: 40044257
The growing use of measurable residual disease (MRD) assays across haematology-oncology creates an urgent need for clinicians and researchers to reflect on the biological and clinical rationale of this class...
7.
Schoemans H, Stienissen E, Goris K, Stewart S, Cowden M, Arnahoutova K, et al.
Lancet Haematol
. 2025 Mar;
12(3):e214-e223.
PMID: 40044256
Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand...
8.
Hendricks C, Spadea M, Du Toit J, Gurnari C, Muratori R, Jimenez V, et al.
Lancet Haematol
. 2025 Mar;
12(3):e178-e179.
PMID: 40044255
No abstract available.
9.
Leroy-Melamed M, Wolford T, Smith S, Adewale V, Bloomberg M, McGirr-Crowley A, et al.
Lancet Haematol
. 2025 Mar;
12(3):e176-e177.
PMID: 40044254
No abstract available.
10.